Generic Name and Formulations:
Icatibant 10mg/mL; soln for SC inj; preservative-free.
Shire US, Inc.
Indications for FIRAZYR:
Treatment of acute attacks of hereditary angioedema (HAE).
≥18yrs: 30mg SC in abdominal area; may give additional doses at intervals of at least 6 hours if response inadequate or symptoms recur. Max 3 doses/24hrs.
<18yrs: not recommended.
Advise patients to seek medical attention after treating laryngeal attack given the potential for airway obstruction. Elderly. Labor & delivery. Pregnancy (Cat.C). Nursing mothers.
May attenuate the antihypertensive effect of ACE inhibitors.
Bradykinin B2 receptor antagonist.
Inj site reactions, pyrexia, transaminase increase, dizziness, rash.
Single-use prefilled syringe (3mL)—1, 3
Endocrinology Advisor Articles
- Update on Vitamin D and Calcium Supplements for Reducing Fracture Risk
- Lower Risk for SGLT2i-Associated Genitourinary Infection With DPP-4i
- Severe Hypoglycemia Associated With Increased Mortality Risk in T2D
- Efficacy of CGM in Preterm Infants of Mothers With Diabetes
- SSRIs and SNRIs Linked to Type 2 Diabetes in Children, Adolescents
- High Grip Strength Associated With Lower Risk for Diabetes-Related AEs
- Statin Use for CVD Prevention Increases Diabetes Risk in Overweight Patients
- Optimal Timing of Gastric Bypass and Cholecystectomy When Both Procedures Clinically Indicated
- Does Asthma Contribute to Infertility?
- Short-Term Probiotics Increase Weight Loss in Overweight, Obesity